S&P 500 Hits Record Highs Amid Sector Rotation and Tech Rally

S&P 500

Quick Read

  • S&P 500 closed at a record high above 7,800.
  • Tech and AI stocks like Marvell and Arista drove gains.
  • Biotech firms including Moderna and Tempus AI faced sharp declines.
  • Investors await Fed meeting minutes for clues on future rate policy.

Market Performance and Record Milestones

The U.S. stock market maintained its upward trajectory on Tuesday as major indices reached significant milestones. The S&P 500 achieved a fresh all-time closing high, successfully surpassing the 7,800 level for the first time in history, according to CNBC. The index recorded a gain of 0.58%, marking its fourth consecutive session of positive growth, which represents the best streak for the index in two months. The Nasdaq Composite also reached a new record, rising 0.45% during the session, while the Dow Jones Industrial Average advanced 0.49%. Despite this broad momentum, the small-cap Russell 2000 index bucked the trend, falling 0.6% as it reversed lower from its 21-day moving average.

Sector Divergence: Tech Wins, Biotechs Retreat

The rally was heavily driven by strength in technology and AI-related sectors, particularly infrastructure plays. Chipmakers saw significant gains, with Marvell Technology rising 5.8% following positive revenue guidance, while Advanced Micro Devices climbed 2.8% after receiving a price target hike from Citi analysts citing increased demand for central processing units. Other notable performers included Astera Labs, GE Vernova, Caterpillar, Bloom Energy, and Arista Networks, all of which have seen increased buy interest, as reported by Investor’s Business Daily. These gains reflect a continued, strong investor preference for AI-integrated infrastructure and software solutions.

Conversely, the healthcare and biotech sectors experienced a sharp and painful reversal. Stocks such as Moderna, Guardant Health, 10x Genomics, and Tempus AI faced significant declines, characterized by many analysts as “ugly reversals.” This volatility in the biotech space serves as a stark reminder of the risks associated with sector concentration. The ARK Genomics ETF (ARKG) notably dropped nearly 9% during the session, while the broader ARK Innovation ETF (ARKK) fell 2.5%, reflecting the concentrated impact of these sell-offs on growth-focused portfolios.

Macroeconomic Context and Fed Outlook

Investors are now turning their attention to the upcoming release of the Federal Reserve’s September meeting minutes, scheduled for Wednesday. These documents are expected to provide critical insight into the central bank’s perspective on current economic conditions and the rationale behind their recent decision to raise interest rates, the first such hike since 2023. Meanwhile, the 10-year Treasury yield, which had reached a 22-year high earlier in the week, retreated slightly to 5.27% to 5.286% depending on the reporting window. Despite this brief reprieve in yields, concerns persist regarding foreign demand for U.S. debt. Investor Ray Dalio noted the complexities of the current debtor-creditor relationship between the U.S. and major foreign holders, specifically highlighting that major holders like China may be hesitant to continue accumulating debt, adding a layer of geopolitical caution to the market’s performance. As the market looks toward Wednesday, futures for the Dow, S&P 500, and Nasdaq remain largely flat, suggesting a period of consolidation following the recent record-breaking session.

|
Contributor:Azat TV Editorial
|
Publisher:Azat TV

LATEST NEWS